1.png)
Cost-effectiveness analysis of antiemetics therapy in breast cancer patients with moderate emetogenic chemotherapy in Prof. Dr. Margono Soekarjo Hospital, Indonesia
Abstract
Chemotherapy-induced nausea and vomiting (CINV) significantly reduce the life quality of cancer patients. A 5-HT3 receptor antagonist, corticosteroid, and H2-blocker have been used to control moderate nausea and vomit in cancer patients. The exploration of the cost-effectiveness of several antiemetic combinations in breast cancer patients in Prof. Dr. Margono Soekardjo Hospital, Purwokerto, Indonesia was the aim of this research. Seventy-four Breast cancer patients who have prescribed moderate-emetogenic chemotherapy during the year 2017-1019 were included in this research. There were fifteen patients treated with the combination of ondansetron and dexamethasone (OD). Fourteen patients were treated with the combination of ondansetron and ranitidine (OR). Thirty-five patients were treated using ondansetron, dexamethasone, and ranitidine (ODR) combination. The effectiveness was represented by the absence of acute nausea and vomiting after receiving chemotherapy. The ODR combinations showed the highest effectivity on diminishing nausea and vomiting among breast cancer patients (0.400), followed by the OD combination (0.267) and the OR combination (0.214). However, the ODR combination generates the highest cost (4.6 million rupiahs) compared to other antiemetics combinations. Compared to the combination of ondansetron and dexamethasone, the combination of ODR provides higher ICER (ICER of 13 Million Rupiahs per case prevented) than the combination of OR (ICER of 8.5 million Rupiahs per case prevented). In conclusion, the combination of ondansetron, dexamethasone, and ranitidine generates the highest cost. It also provides the highest effectiveness in preventing nausea and vomiting.
Keywords
Full Text:
PDFReferences
Assessment, I. H. T. (2017). Health Technology Assessment (HTA) Guideline.
Belhekar, M. N., Taur, S. R., & Munshi, R. P. (2014). A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions. Indian Journal of Pharmacology, 46(1), 117–120. https://doi.org/10.4103/0253-7613.125192
Diaby, V., Tawk, R., Sanogo, V., Xiao, H., & Montero, A. J. (2015). A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Research and Treatment, 151(1), 27–40. https://doi.org/10.1007/s10549-015-3383-6
Diener, K. M. (1998). Chemotherapy-induced nausea and vomiting. Journal of Pharmaceutical Care in Pain & Symptom Control, 6(4), 23–50. https://doi.org/10.1300/J088v06n04_03
Engstrom, C., Hernandez, I., Haywood, J., & Lilenbaum, R. (1999). The efficacy and cost effectiveness of new antiemetic guidelines. Oncology Nursing Forum, 26((9)), 1453–1458
GarcÃa-Cortés, M., Lucena, M. I., Pachkoria, K., Borraz, Y., Hidalgo, R., & Andrade, R. J. (2008). Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Alimentary Pharmacology & Therapeutics, 27(9), 780–789. https://doi.org/10.1111/j.1365-2036.2008.03655.x
Greimel, E. R., Winter, R., Kapp, K. S., & Haas, J. (2009). Quality of life and sexual functioning after cervical cancer treatment: a long-term follow-up study. Psychooncology, 18 (5), 476-482
Hesketh, P. J. (2008). Chemotherapy-induced nausea and vomiting. New England Journal of Medicine, 358(23), 2482–2494. https://doi.org/10.1056/NEJMra0706547
Indonesia, M. K. R. (2013). Standar tarif pelayanan kesehatan pada fasilitas kesehatan tingkat pertama dan fasilitas kesehatan tingkat lanjutan dalam penyelenggarakan program jaminan kesehatan
J, Ferlay., M, Ervik., F, Lam., M, Colombet., L, Mery., M, Piñeros., A, Znaor., & B, Soerjomataram. I. (2018). Cancer Today (powered by Globocan 2018)
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011). Global cancer statistics. CA: A Cancer Journal for Clinicians, 61(2), 69–90. https://doi.org/10.3322/caac.20107
Kang, H. J., Loftus, S., DiCristina, C., Green, S., Pong, A., & Zwaan, C. M. (2018). Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: An analysis by age group. Pediatric Blood & Cancer, 65(10), e27273. https://doi.org/10.1002/pbc.27273
Muñoz, M., & Coveñas, R. (2019). Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic Approach. Anti-Cancer Agents in Medicinal Chemistry, 19(1), 92–100. https://doi.org/10.2174/1871520618666180420165401
Navari, R. M. (2015). 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1848(10), 2738–2746. https://doi.org/10.1016/j.bbamem.2015.03.020
Navari, R. M., & Aapro, M. (2016). Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. New England Journal of Medicine, 374(14), 1356–1367. https://doi.org/10.1056/NEJMra1515442
Perez, E. A. (1998). Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting. The Cancer Journal from Scientific American, 4(2), 72–77
Pradermdee, P., Manusirivithaya, S., Tangjitgamol, S., Thavaramara, T., & Sukwattana, P. (2006). Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 89 Suppl 4, S29-36
Schädlich, P. K., Klussmann, Chen, & Rémy. (2013). Annual cost of hospitalization, inpatient rehabilitation, and sick leave for head and neck cancers in Germany. ClinicoEconomics and Outcomes Research, 203. https://doi.org/10.2147/CEOR.S43393
Setiawan, D., Dolk, F. C., Suwantika, A. A., Westra, T. A., WIlschut, J. C., & Postma, M. J. (2016). Cost-utility analysis of human papillomavirus vaccination and cervical screening on cervical cancer patient in Indonesia. Value in Health Regional Issues, 9, 84–92. https://doi.org/10.1016/j.vhri.2015.10.010
Shankar, A., Roy, S., Malik, A., Julka, P., & Rath, G. (2015). Prevention of chemotherapy-induced nausea and vomiting in cancer patients. Asian Pacific Journal of Cancer Prevention, 16(15), 6207–6213. https://doi.org/10.7314/APJCP.2015.16.15.6207
DOI: http://dx.doi.org/10.12928/pharmaciana.v11i3.17650
Refbacks
- There are currently no refbacks.
Copyright (c) 2021 Ida Dzikriyani, Didik Setiawan, M.Sc., Apt
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Office: Faculty of Pharmacy, Universitas Ahmad Dahlan
Jl. Prof. Dr. Soepomo, S.H., Janturan, Warungboto, Umbulharjo, Yogyakarta, Indonesia
Kode pos 55164
Email: pharmaciana@pharm.uad.ac.id